CYP2C8 haplotype structures and their influence on pharmacokinetics of paclitaxel in a Japanese population

被引:28
作者
Saito, Yoshiro
Katori, Noriko
Soyama, Akiko
Nakajima, Yukiko
Yoshitani, Takashi
Kim, Su-Ryang
Fukushima-Uesaka, Hiromi
Kurose, Kouichi
Kaniwa, Nahoko
Ozawa, Shogo
Kamatani, Naoyuki
Komamura, Kazuo
Kamakura, Shiro
Kitakaze, Masafumi
Tomoike, Hitonobu
Sugai, Kenji
Minami, Narihiro
Kimura, Hideo
Goto, Yu-ichi
Minami, Hironobu
Yoshida, Teruhiko
Kunitoh, Hideo
Ohe, Yuichiro
Yamamoto, Noboru
Tamura, Tomohide
Saijo, Nagahiro
Sawada, Jun-Ichi
机构
[1] Natl Inst Hlth Sci, Div Biochem & Immunochem, Setagaya Ku, Tokyo 1588501, Japan
[2] Tokyo Womens Med Univ, Tokyo, Japan
[3] Musashi Hosp, Tokyo, Japan
[4] Natl Ctr Neurol & Psychiat, Natl Inst Neurosci, Tokyo, Japan
[5] Natl Canc Ctr, Natl Canc Ctr, Res Inst, Tokyo, Japan
[6] Natl Cardiovasc Ctr, Res Inst, Suita, Osaka 565, Japan
[7] Natl Canc Ctr Hosp E, Chiba, Japan
关键词
CYP2C8; haplotype; paclitaxel; pharmacokinetics;
D O I
10.1097/FPC.0b013e32805b72c1
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Objective CYP2C8 is known to metabolize various drugs including an anticancer drug paclitaxel. Although large interindividual differences in CYP2C8 enzymatic activity and several nonsynonymous variations were reported, neither haplotype structures nor their associations with pharmacokinetic parameters of paclitaxel were reported. Methods Haplotype structures of the CYP2C8 gene were inferred by an expectation-maximization based program using 40 genetic variations detected in 437 Japanese patients, which included cancer patients. Associations of the haplotypes and paclitaxel pharmacokinetic parameters were analyzed for 199 paclitaxel-administered cancer patients. Results Relatively strong linkage disequilibriums were observed throughout the CYP2C8 gene. We estimated 40 haplotypes without an amino-acid change and nine haplotypes with amino acid changes. The 40 haplotypes were classified into six groups based on network analysis. The patients with heterozygous *IG group haplotypes harboring several intronic variations showed a 2.5-fold higher median area under concentration-time curve of C3'-p-hydroxy-paclitaxel and a 1.6-fold higher median value of C3'-p-hydroxy-paclitaxel/paclitaxel area under concentration-time curve ratio than patients bearing no *IG group haplotypes (P < 0.001 for both comparisons by Mann-Whitney U-test). No statistically significant differences, however, were observed between patients with and without the *IG group (haplotypes) in clearance and area under concentration-time curve of paclitaxel, area under concentration-time curve of 6 alpha-hydroxy-paclitaxel and 6 alpha-, C3'-p-dihydroxy-paclitaxel, and area under concentration-time curve ratio of 6 alpha-hydroxy-paclitaxel/paclitaxell. Conclusion CYP2C8*IG group haplotypes were associated with increased area under concentration-time curve of C3'-p-hydroxy-paclitaxel and area under concentration-time curve ratio of C3'-p-hydroxy-paclitaxel/paclitelxel. Thus, *IG group haplotypes might be associated with reduced CYP2C8 activity, possibly through its reduced protein levels.
引用
收藏
页码:461 / 471
页数:11
相关论文
共 21 条
[1]   CYP2C8 polymorphisms in Caucasians and their relationship with paclitaxel 6α-hydroxylase activity in human liver microsomes [J].
Bahadur, N ;
Leathart, JBS ;
Mutch, E ;
Steimel-Crespi, D ;
Dunn, SA ;
Gilissen, R ;
Van Houdt, J ;
Hendrickx, J ;
Mannens, G ;
Bohets, H ;
Williams, FM ;
Armstrong, M ;
Crespi, CL ;
Daly, AK .
BIOCHEMICAL PHARMACOLOGY, 2002, 64 (11) :1579-1589
[2]  
Baldwin SJ, 1999, BRIT J CLIN PHARMACO, V48, P424
[3]   Median-joining networks for inferring intraspecific phylogenies [J].
Bandelt, HJ ;
Forster, P ;
Röhl, A .
MOLECULAR BIOLOGY AND EVOLUTION, 1999, 16 (01) :37-48
[4]   Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid [J].
Dai, D ;
Zeldin, DC ;
Blaisdell, JA ;
Chanas, B ;
Coulter, SJ ;
Ghanayem, BI ;
Goldstein, JA .
PHARMACOGENETICS, 2001, 11 (07) :597-607
[5]   Human CYP2C8 is transcriptionally regulated by the nuclear receptors constitutive androstane receptor, pregnane X receptor, glucocorticoid receptor, and hepatic nuclear factor 4α [J].
Ferguson, SS ;
Chen, YP ;
LeCluyse, EL ;
Negishi, M ;
Goldstein, JA .
MOLECULAR PHARMACOLOGY, 2005, 68 (03) :747-757
[6]   Association of CYP2C8, CYP3A4, CYP3A5, and ABCB1 polymorphisms with the pharmacokinetics of paclitaxel [J].
Henningsson, A ;
Marsh, S ;
Loos, WJ ;
Karlsson, MO ;
Garsa, A ;
Mross, K ;
Mielke, S ;
Viganò, L ;
Locatelli, A ;
Verweij, J ;
Sparreboom, A ;
McLeod, HL .
CLINICAL CANCER RESEARCH, 2005, 11 (22) :8097-8104
[7]   Functional characterization of five novel CYP2C8 variants, G171S, R186X, R186G, K247R, and K383N, found in a Japanese population [J].
Hichiya, H ;
Tanaka-Kagawa, T ;
Soyama, A ;
Jinno, H ;
Koyano, S ;
Katori, N ;
Matsushima, E ;
Uchiyama, S ;
Tokunaga, H ;
Kimura, H ;
Minami, N ;
Katoh, M ;
Sugai, K ;
Goto, Y ;
Tamura, T ;
Yamamoto, N ;
Ohe, Y ;
Kunitoh, H ;
Nokihara, H ;
Yoshida, T ;
Minami, H ;
Saijo, N ;
Ando, M ;
Ozawa, S ;
Saito, Y ;
Sawada, J .
DRUG METABOLISM AND DISPOSITION, 2005, 33 (05) :630-636
[8]  
Judson R, 2000, Pharmacogenomics, V1, P15, DOI 10.1517/14622416.1.1.15
[9]  
Kitamura Y, 2002, ANN HUM GENET, V66, P183, DOI 10.1017/S0003480002001124
[10]  
LEHNERT M, 1993, J NATL CANC I MONOGR, V15, P63